Ready-to-use CARDENE® I.V. (nicardipine hydrochloride) is available in formulations of 0.2 mg/mL (40 mg in 200 mL) and 0.1 mg/mL (20 mg in 200 mL) in either sodium chloride or dextrose solutions and is administered as a continuous intravenous infusion.1

Dosing of ready-to-use CARDENE® I.V. (nicardipine hydrochloride)

more>

Administration of ready-to-use CARDENE® I.V. (nicardipine hydrochloride)

more>

Indication

CARDENE® I.V. (nicardipine hydrochloride) Premixed Injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or not desirable. For prolonged control of blood pressure, transfer patients to oral medication as soon as their clinical condition permits.1

Important Safety Information

CARDENE I.V. is contraindicated in patients with advanced aortic stenosis.

Hypotension and reflex tachycardia may potentially occur during treatment with CARDENE I.V.; therefore, close monitoring of blood pressure and heart rate is required. If unacceptable hypotension or tachycardia occurs, the infusion should be discontinued.

Slow titration of CARDENE I.V. is recommended in patients with heart failure or significant left ventricular dysfunction, particularly in combination with a beta-blocker.

Close monitoring of response to CARDENE I.V. is advised in patients with angina, heart failure, impaired hepatic function, or renal impairment.

To reduce the possibility of venous thrombosis, phlebitis, local irritation, and extravasation, administer CARDENE I.V. through large peripheral veins or central veins rather than arteries or small peripheral veins. If CARDENE I.V. is administered in a peripheral vein, to minimize the risk of venous irritation, change the site of infusion every 12 hours.

The most common adverse reactions (>3%) are headache, nausea/vomiting, hypotension, and tachycardia.

Please see full Prescribing Information.

References: 1. CARDENE I.V. (nicardipine hydrochloride) Premixed Injection Prescribing Information. Bedminster, NJ: EKR Therapeutics, Inc; 2011.2. Neutel JM, Smith DHG, Wallin D, et al. A comparison of intravenous nicardipine and sodium nitroprusside in the immediate treatment of severe hypertension. Am J Hypertens. 1994;7:623-628. 3. Halpern NA, Goldberg M, Neely C, et al. Postoperative hypertension: a multicenter, prospective, randomized comparison between intravenous nicardipine and sodium nitroprusside. Crit Care Med. 1992;20(12):1637-1643. 4. IV Nicardipine Study Group. Efficacy and safety of intravenous nicardipine in the control of postoperative hypertension. Chest. 1991;99(2):393-398. 5. Roitberg BZ, Hardman J, Urbaniak K, et al. Prospective randomized comparison of safety and efficacy of nicardipine and nitroprusside drip for control of hypertension in the neurosurgical intensive care unit. Neurosurgery. 2008;63(1):115-121.

STAY UP-TO-DATE

Get Timely Information

> Register to receive the latest
   product and condition-related
   information and resources

MANAGEMENT GUIDELINES

2003 JNC 7 Report (BP reduction)
2010 AHA/ASA Guidelines (ICH)
2012 AHA/ASA Guidelines (aSAH)
2013 AHA/ASA Guidelines (AIS)

> See the recommendations